DJ LogicBio announces clinical and corporate updates
Arix Bioscience PLC (ARIX)
LogicBio announces clinical and corporate updates
27-Apr-2021 / 14:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
LogicBio announces clinical and corporate updates
- First patient in Phase I/II SUNRISE trial expected to be enrolled by mid-year 2021
- Company has entered into a strategic collaboration with CANbridge Pharmaceuticals and a research partnership with
Daiichi Sankyo
LONDON, 27 April 2021: Arix Bioscience plc, ("Arix", LSE: ARIX), a global venture capital company focused on investing
in and building breakthrough biotech companies, notes that its portfolio company LogicBio Therapeutics, Inc.
(Nasdaq:LOGC) today announced an update on screening and enrolment activities for the SUNRISE Phase I/II clinical trial
of LB-001, the company's investigational treatment for methylmalonic acidemia (MMA), a rare and life-threatening
genetic disorder.
LogicBio also announced that it has entered into a strategic collaboration with CANbridge Pharmaceuticals and a
research partnership with Daiichi Sankyo. Under the terms of the agreement with CANbridge Pharmaceuticals, LogicBio is
eligible to receive an upfront payment of USD10 million in addition to up to USD581 million in option payments and
milestones payments, as well as up to double-digit royalties.
The announcement can be accessed on LogicBio's website at: https://investor.logicbio.com/press-releases and full text
of the announcement from LogicBio is contained below.
[ENDS]
For more information, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth
phase of our industry to a broader range of investors. www.arixbioscience.com
LogicBio Therapeutics Announces Clinical and Corporate Updates
- First patient for Phase I/II SUNRISE trial expected to be enrolled by mid-year 2021
- Company also entered into strategic collaboration with CANbridge Pharmaceuticals and research partnership with
Daiichi Sankyo
LEXINGTON, Mass., April 27, 2021 -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine
company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through
adulthood, today announced an update on screening and enrollment activities for the SUNRISE Phase I/II clinical trial
of LB-001, the company's investigational treatment for methylmalonic acidemia (MMA) based on LogicBio's proprietary
gene insertion platform, GeneRide.
"The first two patients who entered pre-dosing screening activities did not meet all of the enrollment criteria for the
SUNRISE trial, each for different reasons, and we will continue to screen additional patients in the coming weeks,"
said Daniel Gruskin, M.D., senior vice president and head of clinical development at LogicBio. "With COVID-19
restrictions being lifted in some U.S.states, additional clinical trial sites have recently been activated and have
begun recruiting and screening patients."
"We expect to enroll our first patient in the SUNRISE trial by mid-year 2021, which represents a slight delay from our
earlier communications," said Frederic Chereau, president and chief executive officer of LogicBio. "We are also pleased
to report that we have pre-identified enough patients to fully enroll SUNRISE, assuming a certain number of screening
failures."
Today, LogicBio also announced a strategic collaboration with CANbridge Pharmaceuticals and research partnership with
Daiichi Sankyo.
LogicBio entered into a strategic collaboration with CANbridge Pharmaceuticals for an exclusive option to license
LB-001 in Greater China (China, Taiwan, Hong Kong and Macau). The deal also grants CANbridge a worldwide license with
respect to AAV sL65, the first capsid based on LogicBio's proprietary sAAVyTM platform, to support development and
commercialization of CANbridge's gene therapy programs for Fabry disease and Pompe disease, with options for two
additional indications. Under the terms of the agreement, LogicBio is eligible to receive an upfront payment of USD10
million in addition to up to USD581 million in option payments and milestones payments, as well as up to double-digit
royalties. A separate press release with more details can be found on LogicBio's investor relations website at
investor.logicbio.com
LogicBio also entered into a research collaboration with Daiichi Sankyo for the development of treatments for two
indications based on GeneRide. The agreement also grants Daiichi Sankyo an option to negotiate and acquire
worldwide licenses to LogicBio's development programs in these indications. A separate press release with more details
can be found on LogicBio's investor relations website at investor.logicbio.com.
About LogicBio Therapeutics, Inc.
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms
to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide platform is
a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable
therapeutic protein expression levels. LogicBio's cutting-edge sAAVy capsid development platform is designed to
support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.
For more information, visit https://www.logicbio.com/.
About the SUNRISE Trial
The SUNRISE trial is a multi-center, open-label, Phase 1/2 clinical trial designed to assess the safety and
tolerability of a single intravenous infusion of LB-001 in pediatric patients with methylmalonic acidemia (MMA)
characterized by methylmalonyl-CoA mutase gene (MMUT) mutations. Seven leading centers in the United States and one in
Saudi Arabia are expected to participate. With the aim of evaluating LB-001 at an early age, before irreversible tissue
damage has occurred, the SUNRISE trial is initially enrolling pediatric patients from 3 -12 years old, with the
possibility to include patients as young as 6 months old after meeting certain safety and biomarker parameters. The
SUNRISE trial will evaluate two doses of LB-001. Patients will participate in a pre-dosing observational period, will
be administered a prophylactic steroid regimen, and will be followed for 52 weeks. Secondary and exploratory endpoints
include changes in disease-related biomarkers, including serum methylmalonic acid, clinical outcomes such as growth and
healthcare utilization, and the pharmacodynamic marker albumin-2A.
About LB-001
GeneRide technology utilizes a natural DNA repair process called homologous recombination that enables precise
editing of the genome without the need for exogenous nucleases and promoters that are associated with an increased risk
of immune response and cancer. LB-001 is a first-in-class, single-dose gene-editing therapy for early intervention in
methylmalonic acidemia (MMA) designed using the GeneRide platform to insert a corrective copy of the MMUT gene into
the ALB locus to drive lifelong therapeutic levels of MMUT expression in the liver, the main site of MMUT expression
and activity. LB-001 is delivered to hepatocytes via an engineered rAAV vector utilizing the highly efficient and
selective liver-targeted LK03 capsid (rAAV-LK03). Preclinical assessment in human hepatocytes demonstrated that LB-001
is capable of site-specific insertion. Preclinical in vivo studies found LB-001 to be safe and demonstrated
transduction of hepatocytes, genomic integration, and liver transgene expression. LB-001-corrected hepatocytes in a
mouse model of MMA demonstrated preferential survival and expansion ("selective advantage"), thus contributing to a
progressive increase in hepatic MMUT expression over time. LB-001 resulted in improved growth, metabolic stability, and
survival in MMA mice.
About Methylmalonic Acidemia (MMA)
Methylmalonic acidemia, or MMA, is a rare and life-threatening genetic disorder, affecting 1 in 25,000 to 50,000
newborns. In the most common form of MMA, a mutation in a gene called MMUT prevents the body from properly processing
certain fats and proteins. As a result, toxic metabolites accumulate in the liver, in muscle tissue and in the brain.
Symptoms include vomiting, lethargy, seizures, developmental delays and organ damage. There is no cure for MMA. To
manage the symptoms, patients go on a severely restrictive, low-protein, high-calorie diet, often through a feeding
tube. Even with aggressive management, these patients often experience life-threatening metabolic crises that can cause
permanent neurocognitive damage.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the federal securities laws, including
with respect to the Company's expectation regarding patient enrollment in the SUNRISE trial, its strategic
collaboration with CANbridge Pharmaceuticals, its research partnership with Daiichi Sankyo and the potential of the
GeneRide platform. These are not statements of historical facts and are based on management's beliefs and
assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with
the initiation, cost, timing, progress and results of the Company's current and future research and development
activities and preclinical studies and clinical trials. These risks are discussed in the Company's filings with the
U.S. Securities and Exchange Commission (SEC), including, without limitation, the Company's Annual Report on Form 10-K
filed on March 15, 2021 and the Company's subsequent filings with the SEC. Except as required by law, the Company
assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in
the future.
Media Contacts:
Bill Berry
Berry & Company Public Relations
W: 212-253-8881
C: 917-846-3862
bberry@berrypr.com
Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com
Investor Contacts:
Matt Lane
Gilmartin Group
617-901-7698
matt@gilmartinir.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 100691
EQS News ID: 1188591
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1188591&application_name=news
(END) Dow Jones Newswires
April 27, 2021 09:00 ET (13:00 GMT)
